New Projects information at Drug Development Technology New and updated information from Projects listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Projects information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Xultophy 100/3.6 for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes. Thu, 01 Dec 2016 00:00:00 GMT Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn’s Disease http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease. Tue, 29 Nov 2016 00:00:00 GMT Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. Thu, 24 Nov 2016 00:00:00 GMT Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment. Tue, 22 Nov 2016 00:00:00 GMT Invokamet XR for the Treatment of Type 2 Diabetes in Adults http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults. Thu, 17 Nov 2016 00:00:00 GMT Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma in adult patients. Thu, 27 Oct 2016 23:00:00 GMT Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD) http://www.drugdevelopment-technology.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ http://www.drugdevelopment-technology.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ Exondys 51 (eteplirsen) is an injectable solution developed by Sarepta Therapeutics. Thu, 20 Oct 2016 23:00:00 GMT Carnexiv (carbamazepine) for the Treatment of Partial, Generalised Tonic-clonic Seizures in Adults http://www.drugdevelopment-technology.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/ http://www.drugdevelopment-technology.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/ Carnexiv (carbamazepine) is an injectable formulation developed by Lundbeck for partial, generalised tonic-clonic seizures in adult patients who are unable to temporarily take oral medication. Thu, 13 Oct 2016 23:00:00 GMT Dupixent (dupilumab) for the Treatment of Atopic Dermatitis http://www.drugdevelopment-technology.com/projects/dupixent-dupilumab-for-the-treatment-of-atopic-dermatitis/ http://www.drugdevelopment-technology.com/projects/dupixent-dupilumab-for-the-treatment-of-atopic-dermatitis/ Dupixent (dupilumab) is an investigational drug being developed by Sanofi and Regeneron as a treatment for moderate to severe atopic dermatitis in adult patients. Wed, 12 Oct 2016 23:00:00 GMT Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis http://www.drugdevelopment-technology.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/ http://www.drugdevelopment-technology.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/ Ocrevus (ocrelizumab), developed by Genentech, a member of Roche Group, is indicated for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis. Thu, 06 Oct 2016 23:00:00 GMT Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer http://www.drugdevelopment-technology.com/projects/ibrance-palbociclib-for-the-treatment-of-metastatic-breast-cancer/ http://www.drugdevelopment-technology.com/projects/ibrance-palbociclib-for-the-treatment-of-metastatic-breast-cancer/ Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy. Thu, 29 Sep 2016 23:00:00 GMT Afluria Quadrivalent for Prevention of Infection from Influenza Virus http://www.drugdevelopment-technology.com/projects/afluria-quadrivalent-for-prevention-of-infection-from-influenza-virus/ http://www.drugdevelopment-technology.com/projects/afluria-quadrivalent-for-prevention-of-infection-from-influenza-virus/ Afluria Quadrivalent is an inactivated influenza vaccine developed by Seqirus, which is developed to provide active immunisation against the disease. Tue, 13 Sep 2016 23:00:00 GMT GLS-5700 DNA Vaccine for Prevention of Infection from Zika Virus http://www.drugdevelopment-technology.com/projects/gls-5700-dna-vaccine-for-prevention-of-infection-from-zika-virus/ http://www.drugdevelopment-technology.com/projects/gls-5700-dna-vaccine-for-prevention-of-infection-from-zika-virus/ GLS-5700 is a synthetic vaccine being developed by Inovio Pharmaceuticals and GeneOne Life Sciences to prevent and treat infections caused by the Zika virus. Thu, 08 Sep 2016 23:00:00 GMT Adlyxin (lixisenatide) for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/adlyxin-lixisenatide-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/adlyxin-lixisenatide-for-the-treatment-of-type-2-diabetes/ Adlyxin (lixisenatide) is an injectable solution developed by Sanofi for the treatment of type 2 diabetes in adults. Thu, 01 Sep 2016 23:00:00 GMT Spritam (levetiracetam) for the Treatment of Epilepsy http://www.drugdevelopment-technology.com/projects/spritam-levetiracetam-epilepsy/ http://www.drugdevelopment-technology.com/projects/spritam-levetiracetam-epilepsy/ Spritam (levetiracetam) is an adjunctive therapy indicated for the treatment of seizures in patients with epilepsy, the fourth most common neurological disorder affecting people of all age groups. Tue, 30 Aug 2016 15:39:00 GMT Sivextro for Treatment of Acute Bacterial Skin and Skin Structure Infections http://www.drugdevelopment-technology.com/projects/sivextro-treatment-acute-bacterial-skin-skin-structure-infections/ http://www.drugdevelopment-technology.com/projects/sivextro-treatment-acute-bacterial-skin-skin-structure-infections/ Sivextro (tedizolid phosphate) is an oxazolidinone class antibacterial drug indicated for treatment of adult patients infected with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria. Sun, 28 Aug 2016 23:00:00 GMT Trobalt / Potiga – Treatment for Partial-Onset Seizure http://www.drugdevelopment-technology.com/projects/trobalt-potiga/ http://www.drugdevelopment-technology.com/projects/trobalt-potiga/ Trobalt (ezogabine / retigabine) is indicated for the treatment of partial-onset epileptic seizures in patients aged more than 18 years old. Sun, 28 Aug 2016 23:00:00 GMT Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Paediatric Patients http://www.drugdevelopment-technology.com/projects/dysport-abobotulinumtoxina-for-the-treatment-of-lower-limb-spasticity-in-paediatric-patients/ http://www.drugdevelopment-technology.com/projects/dysport-abobotulinumtoxina-for-the-treatment-of-lower-limb-spasticity-in-paediatric-patients/ Dysport (abobotulinumtoxinA) is an injectable formulation developed by Ipsen Biopharmaceuticals for the treatment of lower limb spasticity in paediatric patients aged two years or older. Thu, 25 Aug 2016 23:00:00 GMT Zubsolv (Buprenorphine and Naloxone) - Maintenance Treatment for Opioid Dependence http://www.drugdevelopment-technology.com/projects/-zubsolv-buprenorphine-naloxone-opioid-dependence/ http://www.drugdevelopment-technology.com/projects/-zubsolv-buprenorphine-naloxone-opioid-dependence/ Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence. Thu, 18 Aug 2016 23:00:00 GMT SUN-101/eFlow for the Treatment of Chronic Obstructive Pulmonary Disease http://www.drugdevelopment-technology.com/projects/sun-101eflow-for-the-treatment-of-chronic-obstructive-pulmonary-disease/ http://www.drugdevelopment-technology.com/projects/sun-101eflow-for-the-treatment-of-chronic-obstructive-pulmonary-disease/ SUN-101 (Glycopyrrolate) is an inhalation solution developed by Sunovion Pharmaceuticals as a treatment for patients with moderate to severe chronic obstructive pulmonary disease (COPD). Thu, 18 Aug 2016 23:00:00 GMT